Kato T, Takamoto S, Ota K
Gan To Kagaku Ryoho. 1986 Dec;13(12):3401-7.
The antitumor activity of 1.3.3.5.5-pentaziridino-1-thia-2.4.6-triaza-3.5-diphospho rine-1-oxide (SOAz) was investigated in vitro and in vivo. The results obtained were as follows: SOAz showed marginal cytotoxicity against growth of L1210 cells cultured in vitro. In the cell-cycle traverse of RPMI 8402 cells, SOAz prolonged the duration of the S phase, leading to the eventual accumulation of cells at the G2 phase. At the highest concentration, SOAz stopped the cell cycle progression completely. SOAz was found to have similar activity to carbazilquinone, cyclophosphamide or mitomycin C on P388 leukemia. SOAz showed marked antitumor effect against early-stage L1210 leukemia, and was also effective against advanced-stage L1210 leukemia. The therapeutic efficacy of SOAz depends on the treatment schedule. Single injection and intermittent treatment were superior to daily treatment. Oral administration of SOAz was effective as well as i.p., i.v. and i.m. administration.
研究了1,3,3,5,5-五氮杂环丁烷-1-硫杂-2,4,6-三氮杂-3,5-二磷杂环庚烷-1-氧化物(SOAz)的体内外抗肿瘤活性。所得结果如下:SOAz对体外培养的L1210细胞生长显示出轻微的细胞毒性。在RPMI 8402细胞的细胞周期进程中,SOAz延长了S期的持续时间,最终导致细胞在G2期积累。在最高浓度下,SOAz完全阻止了细胞周期进程。发现SOAz对P388白血病的活性与卡巴醌、环磷酰胺或丝裂霉素C相似。SOAz对早期L1210白血病显示出显著的抗肿瘤作用,对晚期L1210白血病也有效。SOAz的治疗效果取决于治疗方案。单次注射和间歇治疗优于每日治疗。SOAz口服给药与腹腔注射、静脉注射和肌肉注射一样有效。